FDA clears biphasic external defibrillator:
This article was originally published in Clinica
The US FDA has cleared Zoll Medicals' external defibrillator, which uses the company's biphasic waveform technology, to treat both ventricular and atrial fibrillation (VF and AF). The device, claimed to be the first external biphasic defibrillator to win US clearance for both VF and AF, has a 68% first-shock efficacy in AF patients compared with only 21% for conventional monophasic technology, said the Burlington, Massachusetts-based company. In a study of VF patients, the biphasic waveform device converted 99% of them on the first shock compared with 93% converted with conventional waveform.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.